Paper Details

  1. Home
  2. Paper Details

Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis.

Author: McCartyJ M, PierceP F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Cefprozil given for 5 days was as effective as clarithromycin given for 10 days in the treatment of acute exacerbation of chronic bronchitis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Shorter than traditional 7- to 14-day treatment regimens have demonstrated efficacy in treatment of an acute exacerbation of chronic bronchitis (AECB). OBJECTIVE: Perform a clinical efficacy study comparing 5 days of cefprozil therapy to 10 days of clarithromycin in treating an AECB. M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1081-1206(10)62248-X

データ提供：米国国立医学図書館（NLM）

Shortening Treatment Regimens for Acute Exacerbation of Chronic Bronchitis

Chronic bronchitis, a common respiratory condition, can lead to debilitating exacerbations. This study investigates the efficacy of shorter treatment regimens for acute exacerbation of chronic bronchitis (AECB), comparing 5 days of cefprozil therapy to 10 days of clarithromycin therapy. The researchers evaluated clinical cure rates and safety profiles for both treatment regimens, exploring the potential for shorter treatment courses while maintaining effectiveness.

Cefprozil: A Viable Alternative for Short-Term Treatment

The study found that 5 days of cefprozil was as effective as 10 days of clarithromycin in treating AECB. Clinical cure rates were comparable for both treatment groups, with no statistically significant differences observed. The study also reported similar safety profiles for both antibiotics, with the most common side effects being nausea and diarrhea.

Optimizing Treatment for AECB

This research provides evidence for the effectiveness of shorter treatment regimens for AECB, potentially reducing the duration of antibiotic therapy while maintaining clinical cure rates. The study's findings suggest that cefprozil can be a viable alternative to clarithromycin for treating AECB, offering a potentially more convenient and cost-effective option for patients.

Dr.Camel's Conclusion

This research is like a well-worn camel trail, guiding us towards a more efficient approach to treating AECB. The study's findings suggest that shorter treatment regimens using cefprozil can be just as effective as longer regimens using clarithromycin. This discovery offers a potential path towards a more streamlined and patient-friendly approach to managing AECB.

Date :
  1. Date Completed 2001-12-04
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

11686426

DOI: Digital Object Identifier

10.1016/S1081-1206(10)62248-X

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.